Core Viewpoint - Eli Lilly (LLY.US) has suspended the shipment of its weight loss drug Mounjaro in the UK, with a new price increase set to take effect next month [1] Group 1: Company Actions - The company has reserved allocations for pharmacies and suppliers to manage supply and ensure continuous access for patients [1] - Legal measures have been taken to prevent suppliers from hoarding the drug, with orders expected to resume on September 1 [1] Group 2: Pricing Strategy - Eli Lilly plans to increase the price of Mounjaro in the UK by up to 170%, raising the monthly supply price from £122 to £330 for the highest dosage [1] - Despite the significant price hike, the company has committed not to raise the supply price to the National Health Service (NHS) to ensure ongoing availability of the drug [1]

Group 1 - The company Eli Lilly has suspended the shipment of its weight loss drug Mounjaro in the UK, with a new price increase set to take effect next month [1] - To manage supply and ensure patients can continuously access the medication, the company has allocated quotas for pharmacies and suppliers that order the drug [1] - Eli Lilly plans to raise the price of Mounjaro in the UK by up to 170% in September, with the highest dosage monthly supply price increasing from £122 to £330 (approximately $164.81 to $445.80) [1] Group 2 - The company has taken legal measures to prevent suppliers from improperly stockpiling the medication [1] - Orders are set to resume on September 1 [1] - The price increase comes amid pressure from the White House for pharmaceutical companies to raise drug prices in Europe to create room for price reductions in the US [1]